₩79,600.00
+0.00 (+0.00%)
KRW · as of 2026-08-19 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where 000100.KS is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
101 interventional · 6 observational · 1 expanded access · 2 with posted results
Held by 0 tracked-famous managers · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| Clinical Trial of YH32367 in Patients With HER2 Positive Locally Advanced or Metastatic Solid TumorNCT05523947Treatment-emergent adverse events (TEAEs) up to Day 21Open-label · Treatment | Phase 1/2 | Recruiting | Drug: YH32367 | HER2-Positive Solid Tumor | 147 | 2028-03-31 | in 588 d | 2026-07-16 |
| A Phase 1/2, Open-label, Multicenter, FIH Study to Evaluate Safety, Tolerability, PK and Anti-tumor Activity of YH42946NCT06616766Treatment Emergent Adverse Events(TEAE)sOpen-label · Treatment | Phase 1/2 | Recruiting | Drug: YH42946 | NSCLC (Non-small Cell Lung Cancer), Solid Tumor | 201 | 2028-03-15 | in 572 d | 2026-08-17 |
| Clinical Trial of YH32364 in Patients With Locally Advanced or Metastatic EGFR Overexpressing Solid TumorsNCT06975410Treatment-emergent adverse events (TEAEs) including dose limiting toxicities (DLTs)Open-label · Treatment | Phase 1/2 | Recruiting | Drug: YH32364 | EGFR Overexpression, Locally Advanced Solid Tumor, Metastatic Solid Tumor | 80 | Jun 2027 | ≤ 313 d | 2026-06-10 |
| Phase 2 Study of Lesigercept in Adult Patients With Chronic Spontaneous Urticaria Who Are Inadequately Controlled by H1-AntihistaminesNCT07415551Change from baseline Urticaria Activity Score over 7 days (UAS7) at Week 12Randomized · Quadruple-masked · Treatment | Phase 2 | Recruiting | Drug: Lesigercept, Placebo | Allergic Diseases, Chronic Spontaneous Urticaria (CSU) | 150 | 2027-06-19 | in 302 d | 2026-04-15 |
| Study to Evaluate the Efficacy and Safety of TEL/AML/CTD in Elderly Patients with Essential HypertensionNCT06282549observationalPercentage of MACCE(Major Adverse Cardiovascular and Cerebrovascular Events) | — | Active, not recruiting | Drug: Telmisartan/Amlodipine/Chlorthalidone(Truset) | Essential Hypertension | 1,219 | 2027-03-31 | in 222 d | 2024-11-19 |
| A First-in-Human, Single- and Multiple-Ascending Dose Study of YH35995 in Healthy Adult Male ParticipantsNCT06517914[Part A, B] Treatment-emergent adverse events (TEAEs)Randomized · Double-masked · Treatment | Phase 1 | Active, not recruiting | Drug: YH35995, Placebo | Healthy Participants | 94 | Mar 2027 | ≤ 222 d | 2026-07-28 |
| Korean Registry of Non-Small Cell Lung Cancer Patients with EGFR MutationNCT06247280observationalClinical characteristics of NSCLC patients with EGFR mutation | — | Active, not recruiting | — | NSCLC | 2,001 | 2026-12-31 | in 132 d | 2024-12-06 |
| Bioequivalence Study Between YHP2508C and YHR2603 in Healthy SubjectsNCT07584304Area under the plasma drug concentration-time curve [AUCt]Randomized · Quadruple-masked · Treatment | Phase 1 | Not yet recruiting | Drug: YHP2508C, YHR2603 | Healthy Subjects | 44 | 2026-09-15 | in 25 d | 2026-05-13 |
| Study to Evaluate the Efficacy and Safety of TEL/AML/CTD in Elderly Patients With Essential HypertensionNCT06041529Mean Systolic Blood Pressure (MSBP) in nighttimeRandomized · Open-label · Treatment | Phase 4 | Active, not recruiting | Drug: Telmisartan/Amlodipine/Chlorthalidone 40/5/12.5 mg, Telmisartan/Amlodipine/Hydrochlorothiazide 40/5/25 mg | Essential Hypertension | 198 | 2026-02-28 | — | 2026-02-13 |
| An Observational, Prospective Study to Assess the Efficacy and Safety of Adalloce in Patients With RA and ASNCT05835518observationalChanges in quality of life (EQ-5D-5L) scores at 52 weeks from baseline in patients with RA and AS | — | Recruiting | — | Rheumatoid Arthritis, Ankylosing Spondylitis | 1,000 | 2025-12-31 | — | 2023-05-09 |
| Clinical Trial to Evaluate the Safety and Efficacy of NTCB02-1 in Patients Who Require Parenteral NutritionNCT06625957Occurance rate of adverse drug reactionRandomized · Open-label · Treatment | Phase 3 | Recruiting | Drug: NTCB02-1, NTCB-C | Parenteral Nutrition | 60 | 2025-07-18 | — | 2025-01-07 |
| Bioequivalence (BE) Study Between YHP2511 and YHP2511A in Healthy VolunteersNCT07470125Area under the plasma drug concentration-time curve [AUCt]Randomized · Open-label · Treatment | Phase 1 | Completed | Drug: YHP2511, YHP2511A | Healthy Subjects | 61 | 2026-07-11actual | — | 2026-07-22 |
| Clinical Trial to Evaluate the Efficacy and Safety of YHP2401 Compared to YHR2402 and YHR2403 for Acute BronchitisNCT07111468Bronchitis Severity Score(BSS)Randomized · Double-masked · Treatment | Phase 3 | Completed | Drug: YHP2401, YHR2402, YHR2403 | Acute Bronchitis | 286 | 2026-01-15actual | — | 2026-02-09 |
| Bioequivalence Study Between YHP2406 and YHR2501 in Healthy SubjectsNCT07265167Area under the plasma drug concentration-time curve [AUCt]Randomized · Open-label · Treatment | Phase 1 | Completed | Drug: YHP2406, YHR2501 | Healthy Subjects | 63 | 2025-10-20actual | — | 2025-12-04 |
| Bioequivalence Study betweenYHP2406 and YHR2501 in Healthy SubjectsNCT06920719Area under the plasma drug concentration-time curve [AUCt]Randomized · Open-label · Treatment | Phase 1 | Completed | Drug: YHP2406, YHR2501 | Healthy Subject | 64 | 2025-07-01actual | — | 2025-07-24 |
| Bioequivalence Study betweenYHP2407 and YHR2502 in Healthy SubjectsNCT06926387Area under the plasma drug concentration-time curve [AUCt]Randomized · Open-label · Treatment | Phase 1 | Completed | Drug: YHP2407, YHR2502 | Healthy Volunteer | 43 | 2025-04-19actual | — | 2025-05-13 |
| Clinical Trial to Evaluate the Safety and Efficacy of NTCB01-1 in Patients Who Require Parenteral NutritionNCT06625931Occurance rate of adverse drug reactionRandomized · Open-label · Treatment | Phase 3 | Completed | Drug: NTCB01-1, NTCB-P | Parenteral Nutrition | 60 | 2025-03-28actual | — | 2025-05-15 |
| Bioequivalence (BE) Study Between YHP2205 and YHR2401 in Healthy VolunteersNCT06775522Area under the plasma drug concentration-time curve [AUCt]Randomized · Open-label · Treatment | Phase 1 | Completed | Drug: YHP2205, YHR2401 | Healthy Volunteers | 60 | 2025-01-20actual | — | 2025-02-03 |
| A Multiple Ascending Dose, Phase 1b Study of YH35324 in Atopic Healthy Subjects or Subjects With Allergic DiseasesNCT05564221Occurrence and severity of adverse events (AEs)Randomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: YH35324, Placebo, Omalizumab | Atopic Healthy Subjects, Adult Subjects With Allergic Diseases | 46 | 2024-11-28actual | — | 2025-01-24 |
| Clinical Trial to Evaluate the PK Interactions of YHR2402 Monotherapy and YHR2402 and YHR2403 Co-Administration in Healthy VolunteersNCT06623526Area under the plasma drug concentration-time curve [AUCt]Randomized · Open-label · Treatment | Phase 1 | Completed | Drug: YHR2402, YHR2402+YHR2403 | Healthy Volunteers | 26 | 2024-11-06actual | — | 2024-11-22 |
| Bioequivalence Study Between YHP2305 and YHR2404 in Healthy VolunteersNCT06613139Area under the plasma drug concentration-time curve [AUCt]Randomized · Open-label · Treatment | Phase 1 | Completed | Drug: YHP2305, YHR2404 | Healthy Volunteers | 34 | 2024-10-15actual | — | 2024-11-15 |
| A Single Dose, Phase 1 Study of YH35324 in Patients with Various Allergic DiseasesNCT05960708Occurrence and severity of adverse events (AEs)Randomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: YH35324, Omalizumab, Placebo | Allergic Disease, Chronic Spontaneous Urticaria, Chronic Inducible Urticaria, Cold Urticaria | 30 | 2024-09-13actual | — | 2024-11-22 |
| Bioequivalence Study Between YHP2205 and YHR2401 in Healthy VolunteersNCT06359626Area under the plasma drug concentration-time curve [AUCt]Randomized · Open-label · Treatment | Phase 1 | Completed | Drug: YHP2205, YHR2401 | Healthy Volunteers | 60 | 2024-06-30actual | — | 2024-11-12 |
| Multicenter, Prospective, Non-interventional, Observational Study to Confirm the Long-term Efficacy and Safety of Rosuampin Tab. in Patients With Hypertension and HypercholesterolemiaNCT06293261observationalOccurence rate of MACCE(Major Adverse Cardiovascular and Cerebrovascular Events) | — | Completed | Drug: Rosuampin 5/5mg, 10/5mg, 20/5mg, 10/10mg | Hypertension, Hypercholesterolemia | 5,047 | 2024-03-31actual | — | 2025-01-22 |
| A Study to Compare the Effects of Sarpogrelate Sustained Release /Aspirin Combination Therapy Versus Aspirin on Blood Viscosity in the Patients With Peripheral Arterial Disease and Coronary Artery DiseaseNCT05730621Change from baseline to week 12 in Blood Viscosity(cP, centipoise) measured by the blood viscometerRandomized · Open-label · Treatment | Phase 4 | Completed | Drug: Sarpogrelate Sustained Release/Aspirin, Aspirin | Sarpogrelate, Blood Viscosity, Peripheral Arterial Disease, Coronary Artery Disease | 68 | 2024-02-28actual | — | 2025-01-22 |
| Clinical Trial to Evaluate the Efficacy and Safety of Sarpogrelate SR in Patients With Chronic Artery Occlusive DiseaseNCT06046196Change in Ankle-Brachial Index (ABI)Randomized · Open-label · Treatment | Phase 4 | Completed | Drug: Sarpogrelate SR, Sarpogrelate | Arterial Occlusive Diseases, Intermittent Claudication | 148 | 2023-03-09actual | — | 2023-09-21 |
| A FIH Study of YH35324 in Atopic Healthy Subjects or Subjects with Mild Allergic DiseasesNCT05061524To evaluate the safety and tolerability following single administration of YH35324Randomized · Double-masked · Treatment | Phase 1 | Completed | Drug: YH35324, Placebo, Omalizumab | Atopic Healthy Subjects, Adult Subjects with Mild Allergic Diseases | 68 | 2023-01-25actual | — | 2024-12-03 |
| A Randomized, Active-controlled, Parallel, Open-label, Multicenter, Phase 4 Study to Compare the Efficacy and Safety of Pregabalin Sustained Release Tablet and Pregabalin Immediate Release Capsule in Type II Diabetic Patients With Peripheral Neuropathic PainNCT05624853Change from baseline to week 8 in Visual Analogue Scale(VAS)Randomized · Open-label · Treatment | Phase 4 | Completed | Drug: pregabalin sustained release tablet, pregabalin immediate release capsule | Neuropathic Pain, Diabetes Mellitus, Type 2 | 130 | 2022-12-20actual | — | 2023-10-23 |
| Pregabalin and Alpha-lipoic Acid Combination Versus Each Monotherapy in Patients With Diabetic Peripheral NeuropathyNCT04846673visual analogue scale (VAS)Randomized · Open-label · Treatment | Phase 4 | Completed | Drug: Pregabalin 150mg + Alpha-lipoic acid 480mg, Pregabalin 150mg, Alpha-Lipoic Acid 480mg | Diabetic Peripheral Neuropathy | 151 | 2022-11-30actual | — | 2025-04-03 |
| Clinical Trial of YH25448(Lazertinib) as the First-line Treatment in Patients With EGFR Mutation Positive Locally Advanced or Metastatic NSCLC (LASER301)NCT04248829results2024-03-22Progression-Free Survival (PFS) According to RECIST v1.1 by Investigator AssessmentRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Lazertinib 240 mg/160 mg, Gefitinib 250 mg, Lazertinib-matching placebo 240 mg/160 mg, Gefitinib-matching placebo 250 mg | Non-Small Cell Lung Cancer | 393 | 2022-07-29actual | — | 2026-06-29 |
| A Study to Evaluate the Pharmacokinetics and Safety of YHD1119 in Subjects With Renal Impairment and Healthy SubjectsNCT05012436CmaxRandomized · Open-label · Treatment | Phase 1 | Completed | Drug: YHD1119 75mg | Healthy Volunteer, Renal Impairments | 16 | 2022-05-10actual | — | 2022-06-30 |
| Retrospective, External Comparator Study of Lazertinib as the 2nd-Line Treatment in Patients With EGFR Mutation+ NSCLCNCT05862194observationalComparative evaluation of (real-world:rw) Progression-free survival (PFS) between patients receiving Lazertinib versus Platinum-based Chemotherapy | — | Completed | Drug: Lazertinib, Platinum-based Chemotherapy | Non-small Cell Lung Cancer | 534 | 2022-04-30actual | — | 2023-08-22 |
| Clinical Trial to Assess Bioequivalence of Lazertinib Between Two Formulations in Healthy Volunteers.NCT05162274AUClast of YH25448Randomized · Open-label · Treatment | Phase 1 | Completed | Drug: Lazertinib(G001), Lazertinib(G002) | Healthy Adult Volunteers | 38 | 2022-01-14actual | — | 2024-12-11 |
| Multi-center, Prospective, Cohort Study to Evaluate the Relationship of Stroke Recurrence and Anti-platelet Resistance in Ischemic Stroke PatientsNCT03823274observationalevaluate the relationship of stroke recurrence and anti-platelet resitance | — | Completed | Drug: Aspirin, Clopidogrel | Ischemic Stroke | 1,011 | 2022-01-03actual | — | 2022-10-12 |
| HMG-CoA Reductase add-on in Chronic Kidney Disease Patients With ProteinuriaNCT03550859Rate of change from baseline to week 48 in Urine Protein to Creatinine Ratio (UPCR)Randomized · Open-label · Treatment | Phase 4 | Unknown status | Drug: Telmisartan/Rosuvastatin 40/10mg, Telmisartan 40mg | Chronic Kidney Disease, Proteinuria | 374 | Dec 2021 | — | 2020-12-14 |
| High-intensity Rosuvastatin vs. Moderate-intensity Rosuvastatin/Ezetimibe in High Atherosclerotic Cardiovascular Disease Risk Patients With Type 2 DiabetesNCT03403556Mean percent change from baseline to week 24 in low-density lipoprotein cholesterol (LDL-C)Randomized · Open-label · Treatment | Phase 4 | Unknown status | Drug: Rosuvamibe, Monorova | Atherosclerotic Cardiovascular Disease, Type 2 Diabetes | 140 | Oct 2021 | — | 2020-12-14 |
| Rosuvastatin/Amlodipine vs Atorvastatin/Amlodipine in Hypertension Patient With DyslipidemiaNCT03951207Rate of change from baseline to week 8 in LDL-CholesterolRandomized · Open-label · Treatment | Phase 4 | Completed | Drug: Rosuampin 10/5mg, Rosuampin 20/5mg, Amlodipine/Atorvastatin 5/20mg | Dyslipidemias, Hypertension | 259 | 2021-09-29actual | — | 2022-10-12 |
| Clinical Trial of YH25448 in Patients with EGFR Mutation Positive Advanced NSCLCNCT03046992Safety and tolerability by Common Terminology Criteria for Adverse Events (CTCAE) v4.03Open-label · Treatment | Phase 1/2 | Completed | Drug: YH25448 | EGFR Gene Mutation | 224 | 2021-01-08actual | — | 2025-03-21 |
| Anagre Cap. in Patients With High-Risk Essential ThrombocythemiaNCT03232177response rate for less than 60 X 10^4/ul in platelet countOpen-label · Treatment | Phase 4 | Completed | Drug: Anagre Cap. | Essential Thrombocythemia | 70 | 2020-12-05actual | — | 2021-07-21 |
| Duowell® vs. Telmisartan Monotherapy in Mild Dyslipidemia Patients With HypertensionNCT03267329Changes from baseline in mean central systolic blood pressureRandomized · Open-label · Treatment | Phase 4 | Completed | Drug: Duowell®, Telmisartan | Hypertension, Dyslipidemia | 80 | 2020-09-02actual | — | 2021-04-06 |
| Rosuvastatin/Ezetimibe Versus Rosuvastatin in ASCVD Patients With Type 2 DMNCT03597412Change from baseline to week 24 in LDL-C levelRandomized · Open-label · Treatment | Phase 4 | Completed | Drug: Rosuvamibe, Monorova | Atherosclerotic Cardiovascular Disease, Type 2 Diabetes Mellitus | 236 | 2020-08-12actual | — | 2020-12-14 |
| Bioequivalence Study Between YHP1906 Tab. 5 mg and YHR1902 Tab. 5 mgNCT04316065Area under the plasma drug concentration-time curve [AUCt]Randomized · Open-label · Treatment | Phase 1 | Completed | Drug: YHP1906, YHR1902 | Healthy Volunteers | 30 | 2020-04-20actual | — | 2020-05-26 |
| BE Study of Two Formulations of Rivaroxaban 2.5 mg in Healthy SubjectsNCT05418803AUCtRandomized · Open-label · Treatment | Phase 1 | Completed | Drug: YHP1807 Tab. 2.5mg, YHR1901 Tab. 2.5mg | Healthy Volunteer | 34 | 2020-02-14actual | — | 2022-06-16 |
| Clinical Trial to Evaluate the Safety and Pharmacokinetics of YHP1903 in Healthy VolunteersNCT04225052AUCtRandomized · Open-label · Treatment | Phase 1 | Completed | Drug: YHP1903, Champix | Healthy Volunteer | 34 | 2020-01-08actual | — | 2020-01-23 |
| A Study to Evaluate the Effect of Sarpogrelate on Blood HyperviscosityNCT03509922Change from baseline to week 24 in tissue oxygen delivery index (tODI)Randomized · Open-label · Treatment | Phase 4 | Completed | Drug: Anplag Tab. 100mg bid, Anplag Tab. 100mg tid | Peripheral Artery Disease, PAD | 60 | 2019-12-26actual | — | 2020-06-23 |
| High-intensity Rosuvastatin and Moderate-intensity Rosuvastatin/Ezetimibe in ASCVD PatientsNCT03494270Change from baseline to week 12 in LDL-C levelRandomized · Open-label · Treatment | Phase 4 | Completed | Drug: Rosuvamibe, Monorova | ASCVD | 270 | 2019-09-26actual | — | 2019-12-30 |
| Comparison of High-dose Rosuvastatin Versus Low-dose Rosuvastatin Plus Ezetimibe on Carotid Plaque Inflammation in Patients With Acute Coronary SyndromeNCT04056169Percent change in most-diseased segment (MDS)-tissue blood ratio (TBR) of the index vesselRandomized · Open-label · Treatment | Phase 4 | Completed | Drug: high-dose rosuvastatin, low-dose rosuvastatin plus ezetimibe | Acute Coronary Syndrome, Carotid Atherosclerotic Plaque With Inflammation | 50 | 2019-07-23actual | — | 2019-08-16 |
| Effect of Choline Alphoscerate on Cognitive Function in Alzheimer's DementiaNCT03441516ADAS-cogRandomized · Open-label · Treatment | Phase 4 | Unknown status | Drug: Alfoatirin® Tab. + Aripezil® Tab., Aripezil® Tab. | Alzheimer's Disease | 79 | 2019-07-04actual | — | 2020-12-22 |
| High-Dose Statin Combined With Telmisartan vs Amlodipine on Glucose Metabolism in ASCVD Patients With IFG and HypertensionNCT03474562Change from baseline to week 24 in homeostasis model assessment for insulin resistance (HOMA-IR)Randomized · Open-label · Treatment | Phase 4 | Completed | Drug: Duowell®, Monorova® + Amlopin® | ASCVD, Impaired Fasting Glucose, Hypertension | 100 | 2019-06-07actual | — | 2021-06-02 |
| A Study to Compare Rosuvastatin/Ezetimibe and Rosuvastatin in Patients With Diabetes Mellitus and HypercholesterolemiaNCT03217409Low density lipoprotein cholesterol (LDL-C) (%)Randomized · Open-label · Treatment | Phase 4 | Completed | Drug: Rosuvastatin+Ezetimibe, Rosuvastatin | Diabetes Mellitus and Hypercholesterolemia | 85 | 2019-04-03actual | — | 2019-09-23 |
| Rosuvastatin/Ezetimibe vs Rosuvastatin in Korean Patients With Type 2 Diabetes Mellitus and HypercholesterolemiaNCT03446261Change from baseline to week 8 in ApoB/ApoA1 ratioRandomized · Open-label · Treatment | Phase 4 | Completed | Drug: Rosuvamibe® Tab, Monorova® Tab | Type 2 Diabetes Mellitus, Hypercholesterolemia | 140 | 2019-03-05actual | — | 2019-07-23 |
| Clinical Trial to Evaluate the Safety and Effects of Ethnicity and Food on Pharmacokinetics of YH25448NCT03556436AUClast of YH25448Non-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: YH25448 240mg | Non-Small Cell Lung Cancer | 24 | 2018-12-30actual | — | 2019-01-16 |
| Clinical Trial to Compare the Safety and Pharmacokinetics of YH22162 in Healthy VolunteersNCT03662620AUClast of Telmisartan/amlodipine/chlorthalidoneRandomized · Open-label · Treatment | Phase 1 | Completed | Drug: Telmisartan 80mg + Amlodipine 5mg + Chlorthalidone 25mg, Telmisartan 80mg + Amlodipine 5mg + Chlorthalidone 25mg | Hypertension | 67 | 2018-12-08actual | — | 2024-11-12 |
| Clinical Trial to Evaluate the Efficacy and Safety of YHP1701NCT03103256Percent change of LDL-CholesterolRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: YHP1701, YHR1703, YHR1704 | Hypertension and Hyperlipidemia | 106 | 2018-04-30actual | — | 2018-09-07 |
| Clinical Trial of YHD1119 in Patients With Peripheral Neuropathic PainNCT02985216Change From Baseline to End of Treatment (EOT) in Weekly Mean Pain Score on the Daily Pain Rating Scale (DPRS)Randomized · Double-masked · Treatment | Phase 3 | Completed | Drug: YHD1119, Lyrica | Peripheral Neuropathic Pain | 371 | 2018-04-27actual | — | 2019-01-16 |
| A Clinical Trial to Evaluate the Efficacy and Safety of YMC026 in Respiratory Disease PatientsNCT03334916Change from Baseline BSS at Day 6Randomized · Double-masked · Treatment | Phase 4 | Completed | Drug: YMC026, Placebo | Respiratory Disease | 223 | 2018-04-11actual | — | 2019-01-16 |
| Clinical Trial of Temisartan/Amlodipine & Rosuvastatin in Subjects With Hypertension and HyperlipidemiaNCT03067688Mean sitting systolic blood pressure (MSSBP)Randomized · Double-masked · Treatment | Phase 3 | Completed | Drug: Temisartan+Amlodipine+Rosuvastatin (Combination drug), Temisartan+Amlodipine, Temisartan+Rosuvastatin | Hypertension, Hyperlipidemia | 202 | 2018-03-27actual | — | 2019-01-16 |
| A Clinical Trial of YMC017 in Hypertensive and Hypercholesterolemic Patients With Metabolic SyndromeNCT02968160The proportion of subjects that the mean Sitting Diastolic Blood Pressure(siSBP) and Low Density Lipoprotein-Cholesterol(LDL-C) level reach the treatment goals after 8 weeks from investigational product administration.Randomized · Open-label · Treatment | Phase 4 | Terminatedsponsor's stated reason: Due to poor enrollment rate | Drug: Telmisartan 40mg + Rosuvastatin 20mg, Telmisartan 80mg + Rosuvastatin 20mg, Telmisartan 40mg, 80 mg, Rosuvastatin 20mg | Metabolic Syndrome | 55 | Feb 2018actual | — | 2019-04-12 |
| A Clinical Trial to Investigate the Pharmacokinetic Drug Interaction Between YHR1705 and YHR1706NCT03235362YHR1705, YHR1706 AUCtauRandomized · Open-label · Treatment | Phase 1 | Completed | Drug: YHR1705, YHR1706, YHR1705+YHR1706 | Dyslipidemia, Type 2 Diabetes Mellitus | 28 | 2017-09-19actual | — | 2017-11-01 |
| Clinical Trial of YH14755 in Subjects With Dyslipidemia and Type II DiabetesNCT02586129Change in LDL CholesterolRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: YH14755, Metformin, Rosuvastatin | Dyslipidemia, Type II Diabetes | 249 | 2017-07-07actual | — | 2018-10-03 |
| Clinical Trial to Assess the Effect of Food on the Pharmacokinetics of YHD1119 in Healthy VolunteersNCT03191136YHD1119 CmaxRandomized · Open-label · Treatment | Phase 1 | Completed | Drug: YHD1119 300mg, YHD1119 300mg | Peripheral Neuropathic Pain | 24 | 2017-06-27actual | — | 2019-01-16 |
| Clinical Trial to Compare the Safety and Pharmacokinetics of YHP1604 in Comparison to the Co-administration of Telmisartan/Amlodipine and RosuvastatinNCT03116516Telmisartan/Amlodipine/Rosuvastatin Cmax, AUClastRandomized · Open-label · Treatment | Phase 1 | Completed | Drug: Temisartan/Amlodipine+Rosuvastatin, YHP1604 | Hypertension, Hyperlipidemia | 62 | 2017-05-26actual | — | 2019-01-16 |
| A Clinical Trial of YH23537 in Patients With Knee OsteoarthritisNCT02759198Change From Baseline in VAS score to assess pain at Week 12Randomized · Double-masked · Treatment | Phase 2 | Completed | Drug: YH23537, Celecoxib, YH23537 placebo | Knee Osteoarthritis | 456 | 2017-05-24actual | — | 2019-01-16 |
| A Clinical Trial of YH1177 in Patients With Otitis Media and OtorrheaNCT02817347The proportion of patients achieving cessation of otorrhea on Day 15.Randomized · Double-masked · Treatment | Phase 1/2 | Terminatedsponsor's stated reason: Sponsor's decision for the Drug Development. | Drug: piperacillin 4% + tazobactam 0.5% + dexamethasone 0.1%, piperacillin 8% + tazobactam 1.0% + dexamethasone 0.1%, piperacillin 2% + tazobactam 0.25%, piperacillin 4% + tazobactam 0.5%, piperacillin 8% + tazobactam 1.0% | Otitis Media, Otorrhea | 135 | 2017-04-13actual | — | 2022-01-13 |
| A Trial to Evaluate the Efficacy and Safety of YH12852 in Patients With Functional DyspepsiaNCT02567578Ratio of OTE (Overall Treatment Efficacy) respondersRandomized · Triple-masked · Treatment | Phase 2 | Terminatedsponsor's stated reason: Technology transfer | Drug: YH12852 0.1 mg, YH12852 0.25 mg, YH12852 0.5 mg, Placebo | Functional Dyspepsia | 12 | 2017-03-16actual | — | 2022-01-13 |
| Efficacy & Safety Study of YH22162 vs Telmisartan/Amlodipine in Patients With Hypertension Inappropriately Controlled on Telmisartan/Amlodipine TreatmentNCT02620163Change From Baseline in Mean Sitting Systolic Blood Pressure (MSSBP) at Week 8Randomized · Double-masked · Treatment | Phase 3 | Completed | Drug: telmisartan/amlodipine 40/5mg, YH22162 40/5/12.5 mg, telmisartan/amlodipine 80/5mg, YH22162 80/5/25 mg, telmisartan/amlodipine 40/5mg placebo, YH22162 40/5/12.5 mg placebo, telmisartan/amlodipine 80/5mg placebo, YH22162 80/5/25 mg placebo | Hypertension | 381 | Dec 2016actual | — | 2024-11-12 |
| A Phase II Clinical Trial of YH23537 in Patients With Chronic Periodontal Disease.NCT02585596Change in probing pocket depth (PD)Randomized · Double-masked · Treatment | Phase 2 | Completed | Drug: YH23537 1000mg/day, YH23537 2000mg/day, YH23537 3000mg/day, placebo | Chronic Periodontitis | 275 | 2016-12-28actual | — | 2019-01-16 |
| Phase 1/2a Trial of YH12852 in Healthy Subjects and Patients With Functional ConstipationNCT02538367Cmax (IR/DR multiple dose cohort and Multiple low-dose IR cohort)Randomized · Double-masked | Phase 1/2 | Completed | Drug: YH12852 IR 0.05mg, YH12852 IR 0.1mg, YH12852 IR 0.3mg, YH12852 IR 0.5mg, YH12852 IR 1mg, YH12852 IR 2mg, YH12852 IR 3mg, YH12852 DR1 0.5mg, YH12852 DR1 1mg, YH12852 DR1 2mg, YH12852 DR1 4mg, YH12852 DR2 8mg, Prucalopride 2mg, Placebo | Functional Constipation | 120 | Sep 2016actual | — | 2016-10-31 |
| A Study to Investigate Pharmacokinetic Drug Interaction and Safety of Telmisartan/Amlodipine and RosuvastatinNCT02951962Telmisartan, Amlodipine, Rosuvastatin AUCτNon-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: Twynsta 80/5mg, Crestor 20mg | Hypertension, Hyperlipidemia | 60 | Sep 2016actual | — | 2017-02-01 |
| A Open-label, Randomized, Crossover Study to Assess PK of PregabalinNCT02783183Cmax,ssRandomized · Open-label · Treatment | Phase 1 | Completed | Drug: YHD1119, Lyrica | Peripheral Nueropathy Pain | 32 | Aug 2016actual | — | 2019-01-16 |
| PK Study of YH22189 FDC Compared to Combination of Telmisartan/Amlodipine and RosuvastatinNCT02608242Telmisartan CmaxRandomized · Open-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: sponsor decision | Drug: YH22189, Twynsta 80/10mg, Crestor 20mg | Hypertension, Hyperlipidemia | 123 | Jun 2016actual | — | 2017-02-01 |
| Clinical Trial of YH14618 in Patients With Degenerative Disc DiseaseNCT02320019Proportion of VAS respondersRandomized · Triple-masked · Treatment | Phase 2 | Completed | Drug: Placebo, YH14618 | Disc Degenerative Disease | 326 | Apr 2016actual | — | 2016-11-10 |
| PK and Food Effect of Pregabalin Study After Dosing in Healthy Male VolunteersNCT02783638Cohort 1: CmaxRandomized · Open-label · Treatment | Phase 1 | Completed | Drug: YHD1119, Lyrica | Peripheral Neuropathy Pain | 64 | Apr 2016actual | — | 2019-01-16 |
| PK Study of YH22162 FDC Compared to Combination of Twynsta and HygrotonNCT02496910Bioequivalence study is based on Cmax and AUC parametersRandomized · Open-label | Phase 1 | Completed | Drug: YH22162, Telmisartan/Amlodipine 80/5 mg (FDC), Chlorthalidone 25mg | Hypertension | 180 | Sep 2015actual | — | 2015-09-25 |
| Safety/Tolerability and Pharmacokinetics/Pharmacodynamics of YH12852 After Oral Administration in Healthy Male SubjectsNCT01870674the number of adverse events, seriousness of adverse eventRandomized · Quadruple-masked · Basic science | Phase 1 | Completed | Drug: YH12852, Prucalopride, Placebo | Healthy | 127 | Apr 2015actual | — | 2015-05-08 |
| Safety and Efficacy of YH14617 in Diabetes MellitusNCT01507038Change from baseline in HbA1c at week 12Randomized · Double-masked · Treatment | Phase 2 | Completed | Drug: YH14617, YH14617, YH14617, Placebo | Diabetes Mellitus | 84 | Jan 2015actual | — | 2015-02-18 |
| The Exploration for Pharmacodynamics and Pharmacokinetics of YH4808 New Formulation in Healthy SubjectsNCT02176668The Cmax of YH4808Randomized · Open-label · Other | Phase 1 | Completed | Drug: YH4808 NF 100, YH4808 OF 200, YH4808 NF 200, YH4808 NF 400 | Healthy | 82 | Nov 2014actual | — | 2022-01-13 |
| Effect of Sarpogrelate On the Nephropathy in Type 2 Diabetes (SONATA Study)NCT01869881ACR(Urine Albumin/Creatinine ratio)Randomized · Double-masked · Treatment | Phase 4 | Completed | Drug: Anplag(Sarpogrelate), Placebo | Diabetic Nephropathy | 151 | 2014-11-17actual | — | 2021-04-23 |
| The Pharmacokinetic Drug-drug Interaction and Safety of Telmisartan/Amlodipine and Rosuvastatin in Healthy Male VolunteersNCT02233218Area under the plasma/serum/blood drug concentration-time curve in steady-state of Telmisartan and AmlodipineNon-randomized · Open-label · Supportive care | Phase 1 | Completed | Drug: Telmisartan, Amlodipine, Rosuvastatin | Healthy Male Volunteer | 60 | Oct 2014actual | — | 2015-02-18 |
| Phase 1 Clinical Trial to Investigate the Effect on the Pharmacokinetics of YH14755 Compared to Co-administration of Rosuvastatin and Metformin SR in Healthy VolunteersNCT02125227AUClast of rosuvastatin and metforminRandomized · Open-label | Phase 1 | Completed | Drug: Rosuvastatin, Metformin, YH14755, YH14755 | Healthy | 56 | Sep 2014actual | — | 2014-10-09 |
| Drug-drug Interaction Study (Telmisartan, Amlodipine, Chlorthalidone)NCT02152969AUCt ss, Cmax ss of telmisartan/amlodipine/chlorthalidoneRandomized · Open-label · Basic science | Phase 1 | Completed | Drug: Telmisartan, Amlodipine, Chlorthalidone | Hypertension | 66 | Aug 2014actual | — | 2014-11-19 |
| Efficacy and Safety Study of YH16410 Versus Rosuvastatin and Telmisartan Monotherapies in Patients With Hypertension and HyperlipidemiaNCT01914432Change in Diastolic Blood Pressure, Change in LDL CholesterolRandomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: YH16410, Rosuvastatin, Telmisartan, YH16410 placebo, Rosuvastatin placebo, Telmisartan placebo | Hyperlipidemia, Hypertension | 210 | Jun 2014actual | — | 2014-07-08 |
| Safety, Tolerability and Efficacy of YH14618 in Patients With Degenerative Disc DiseaseNCT01526330Evaulate the safety and tolerability after single intradiscal administationRandomized · Triple-masked · Treatment | Phase 1/2 | Completed | Drug: YH14618, YH14618, YH14618, Placebo | Degenerative Disc Disease | 48 | Jan 2014actual | — | 2015-05-29 |
| Study to Investigate the Safety, Tolerability and Efficacy of YH4808 in Patients With Reflux EsophagitisNCT01538849Number of Participants With Healing of Reflux Esophagitis (RE) Who Were "Normal(including minimal change)" at Week 4 Out of Patients Who Were Graded "A, B, C or D" at Baseline According to Los Angeles ClassificationRandomized · Double-masked · Treatment | Phase 2 | Completed | Drug: Esomeprazole 40mg, YH4808 A mg, YH4808 B mg, YH4808 C mg | Reflux Esophagitis | 154 | Nov 2013actual | — | 2014-07-10 |
| The PK and PD Interaction Between YH4808, Amoxicillin and Clarithromycin in Healthy SubjectsNCT01921647Cmax, AUClast of YH4808, M3, amoxicillin, clarithromycin, 14-hydroxyclarithromycinRandomized · Open-label · Supportive care | Phase 1 | Completed | Drug: YH4808, Nexium, Amoxicillin, clarithromycin | Healthy | 95 | Nov 2013actual | — | 2013-12-03 |
| Phase 2 Clinical Trial to Investigate the Safety, Tolerability and Efficacy of YH1885L in Patients With Non-erosive Reflux Disease(NERD)NCT01750437the rate of subject who had 'complete recovery' of symptom after 4 week administrationRandomized · Double-masked · Treatment | Phase 2 | Completed | Drug: YH1885L(Revaprazan), Esomeprazole 20mg, placebo | Non-erosive Reflux Disease | 149 | Oct 2013actual | — | 2014-07-10 |
| Pharmacokinetic Drug Interaction Between YH4808 and DiclofenacNCT01876615Cmax of YH4808Randomized · Open-label · Supportive care | Phase 1 | Completed | Drug: YH4808, Diclofenac, YH4808+Diclofenac | Healthy | 49 | Oct 2013actual | — | 2014-01-01 |
| PK Study of Telmisartan/Rosuvastatin FDC Compared to Combination of Telmisartan and RosuvastatinNCT01975961plasma pharmacokinetic parameters for telmisartan and rosuvastatin in relevant treatmentsRandomized · Open-label | Phase 1 | Completed | Drug: Crestor 20mg(Rosuvastatin 20mg), Micardis 80mg(Telmisartan 80mg) , FDC | Dyslipidemia & Hypertension | 185 | Aug 2013actual | — | 2013-11-05 |
| A Clinical Trial of YH14642 in Patients With Chronic Periodontal DiseaseNCT01499225Change in probing pocket depth (PD)Randomized · Double-masked · Treatment | Phase 2 | Completed | Drug: YH14642 500mg Tab, YH14642 500mg Tab, YH14642 500mg Tab, INSADOL[Zea mays L. extract] 35mg Tab, DENTISTA[Doxycycline hyclate] 20mg Cap, Placebo | Chronic Periodontitis | 162 | Jul 2013actual | — | 2014-07-31 |
| Investigate the Safety/Tolerability and Efficacy of Bilastine 20mg in Korean Patients With Seasonal Allergic RhinitisNCT01400828AUC of TSSRandomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: Bilastine, Desloratadine, Placebo | Seasonal Allergic Rhinitis | 239 | Jun 2013actual | — | 2014-07-10 |
| Safety and Efficacy of YHD001 in AsthmaNCT01424124Change from baseline of FEV1 at week 4Randomized · Triple-masked · Treatment | Phase 2 | Completed | Drug: YHD001 dose level 1, YHD001 dose level 2, Singulair, Placebo | Asthma | 56 | Jun 2013actual | — | 2014-07-10 |
| Phase I Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetics of YHB1411-2 in Healthy Male VolunteersNCT01525147Safety EvaluationRandomized · Quadruple-masked · Treatment | Phase 1 | Completed | Biological: YHB1411-2: Level 2, YHB1411-2: Level 3, YHB1411-2: Level 4, YHB1411-2: Level 5, Placebo, YHB1411-2: level 1 | Rheumatic Arthritis | 49 | Jun 2013actual | — | 2014-07-10 |
| Safety and Efficacy of YHD1023 in Erectile DysfunctionNCT01423370Change from baseline in the International Index of Erectile Function(IIEF) - Erectile Function(EF) domain score at week 8Randomized · Double-masked · Treatment | Phase 2 | Completed | Drug: YHD1023, YHD1023, YHD1023, Cialis, Placebo | Erectile Dysfunction | 104 | Mar 2013actual | — | 2014-07-31 |
| AME Study of [14C]-YH4808 in Healthy Male SubjectsNCT01825707PK of a single oral dose of [14C] YH4808 200 mg and its metabolites(M3, M8)Open-label | Phase 1 | Completed | Drug: [14C]-YH4808 200 mg | Healthy | 8 | Mar 2013actual | — | 2014-07-14 |
| YH4808 Postprandial PK/PD Study in Healthy SubjectsNCT01761513Area under the plasma concentration versus time curve of YH4808Randomized · Open-label · Treatment | Phase 1 | Completed | Drug: YH4808, YH4808, YH4808, YH4808 | Healthy | 21 | Feb 2013actual | — | 2014-04-15 |
| A Randomized, Open-label, Multiple-dose, Crossover Study to Investigate the Pharmacokinetic Drug Interaction Between Rosuvastatin and Telmisartan in Healthy VolunteerNCT01992601AUCRandomized · Open-label | Phase 1 | Completed | Drug: Crestor 20mg(Rosuvastatin 20mg), Micardis 80mg(Telmisartan 80mg) | Healthy Volunteer | 48 | Dec 2012actual | — | 2013-11-25 |
| Safety, Tolerability, Pharmacokinetics and Efficacy of YHD1044NCT01419470Safety and tolerabilityRandomized · Triple-masked · Basic science | Phase 1/2 | Completed | Drug: dapoxetine | Premature Ejaculation | 24 | May 2012actual | — | 2012-08-01 |
| Safety/Tolerability and Efficacy of YHD001 in Patients With Acute and Chronic BronchitisNCT01420445Change of total symptom score from baseline to the end of treatmentRandomized · Triple-masked · Treatment | Phase 2 | Completed | Drug: YHD001 dose level 1, YHD001 dose level 2, Pelargonium sidoides extract, placebo | Acute Bronchitis, Chronic Bronchitis | 118 | May 2012actual | — | 2013-09-26 |
| Food Effect on Pharmacokinetics of YH4808 in Healthy Male SubjectsNCT01520012Area under the plasma concentration versus time curve of YH4808Randomized · Open-label · Treatment | Phase 1 | Completed | Drug: YH4808 100 mg, YH4808 100 mg, YH4808 300 mg, YH4808 300 mg, YH4808 300 mg | Healthy | 44 | May 2012actual | — | 2012-07-24 |
| A Phase 1 Clinical Trial to Investigate Pharmacokinetics and Drug Interaction of Crestor and Glucodown OR SR in Healthy VolunteersNCT01526317AUCtauRandomized · Open-label | Phase 1 | Completed | Drug: Crestor 10mg(Rosuvastatin 10mg), Glucodown OR SR 750mg(Metformin SR 750mg) | Pharmacokinetics and Drug Interaction of Crestor and Glucodown SR | 36 | May 2012actual | — | 2012-08-01 |
| Pharmacokinetic Drug Interaction Between Rosuvastatin and ValsartanNCT01609907Cmax,ss of valsartanRandomized · Open-label · Treatment | Phase 1 | Completed | Drug: Rosuvastatin+Valsartan (Sequence 1), Rosuvastatin+Valsartan (Sequence 2), Rosuvastatin+Valsartan (Sequence 3), Rosuvastatin+Valsartan (Sequence 4), Rosuvastatin+Valsartan (Sequence 5), Rosuvastatin+Valsartan (Sequence 6) | Hypertension, Hyperlipidemia | 30 | May 2012actual | — | 2012-06-01 |
| Comparative Pharmacokinetics of YH14659 in Healthy Male SubjectsNCT01657071Cmax and AUCt of clopidogrelRandomized · Open-label · Treatment | Phase 1 | Completed | Drug: YH14659, clopidogrel & aspirin | Acute Coronary Syndrome | 60 | Apr 2012actual | — | 2012-08-03 |
| Comparative Pharmacokinetics of YH14659NCT01422109Maximum plasma concentration(Cmax) of clopidogrelRandomized · Open-label · Treatment | Phase 1 | Completed | Drug: YH14659, clopidogrel & aspirin | Acute Coronary Syndrome | 44 | Nov 2011actual | — | 2012-01-09 |
| Pharmacokinetic Drug Interaction Between Revaprazan and Itopride HCl in Healthy Male SubjectsNCT01332890PharmacokineticsRandomized · Open-label · Treatment | Phase 1 | Completed | Other: Sequence 1, Sequence 2, Sequence 3, Sequence 4, Sequence 5, Sequence 6 | Healthy | 30 | Aug 2011actual | — | 2014-07-10 |
| Randomized, Open-label, Parallel Study to Evaluate the Pharmacokinetic Characteristics of Pregabalin According to Different Controlled Released Formulations in Healthy Male SubjectsNCT01420913Cmax,ssRandomized · Open-label · Screening | Phase 1 | Completed | Drug: Pregabalin | Healthy | 28 | Aug 2011actual | — | 2011-08-22 |
| Safety/Tolerability and Pharmacokinetics/Pharmacodynamics of YH4808 After Oral Administration in Healthy Male SubjectsNCT01007019To evaluate the PKs, PDs, safety and tolerability of escalating, single/multiple oral doses of YH4808Randomized · Double-masked · Basic science | Phase 1 | Completed | Drug: YH4808 30mg, YH4808 50mg, YH4808 100mg, YH4808 200mg, YH4808, YH4808 100mg (repeat dose), YH4808 200mg (repeat dose), YH4808 600mg, YH4808 800mg (single dose), YH4808 400 mg (repeat doses), Placebo, Esomeprazole 40mg | Healthy | 134 | Mar 2011actual | — | 2014-07-10 |
| Bioequivalence Study of Letrozole 2.5 mg TabletsNCT01084499results2019-03-29Letrozole : AUC0-tzRandomized · Open-label · Other | Not applicable | Completed | Drug: Femara (Sequence 1), Peratra (Sequence 1), Femara (Sequence 2), Peratra (Sequence 2) | Healthy | 26 | Apr 2009actual | — | 2019-03-29 |
| Early Access Program of Lazertinib in Republic of KoreaNCT04829422expanded access | — | Approved for marketing | Drug: Lazertinib 240 mg | Lung Cancer | — | — | — | 2022-03-03 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19